Higher costs, dwindling grants in 2005

Share this article:
Pharmaceutical company support for CME increased 4% in 2005 to $1.1 billion, but higher expenses swallowed up any profit for publishing and education companies, according to the annual report of the Accreditation Council for Continuing Medical Education (ACCME), released in July.

“It's rather striking that commercial spending is still growing, but the rate of spending has dropped,” said Eric Peterson, VP, continuing education, Academy for Healthcare Education.
Between 1998 and 2003, commercial funding grew an average of 21% per year. From 2003-2004, it dropped to 9% and to less than half that in 2005. Peterson attributed the slowing growth to pharmaceutical firms adjusting to new, more compliant funding systems since 2003.
If the slowdown in grants has hit bottom, “this will have been a small price to pay to increase the level of compliance and increase the quality of CME offerings,” said Marty Cearnal, EVP, chief strategy officer, Jobson Medical Information.

Due to the decline, grants slipped to 49% of total CME income. Conversely, sales of advertising and exhibit space at meetings, along with registration fees, increased to a 50% share.

Physician member societies continue to be the most profitable providers, with most of their revenue coming from registration fees. Publishing/education companies had the highest gross income, driven partly by a 12% ($67 million) jump in commercial grants. Companies also draw most commercial funding (45%). However, because eight additional education companies began reporting commercial support during the period, the amount of support per provider actually fell 1%.

Expenses also ate into their profits, increasing 13.5%—roughly double the rate of total expense for the entire industry (6.5%).

“There is more internal expense related to what we do to comply with the new [ACCME] Standards for Commercial Support,” Peterson said.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...